For Healthcare Professionals

Strait Access Technologies (SAT) was founded by a small team of clinical and biomedical professionals operating at the interface of the industrialised and the developing world. The founders and a dedicated group of designers, engineers and chemists combine experience and expertise to create innovative medical devices for the heart, and the intellectual property related to the full range of SAT products, is protected by 15 patent families in major industrialised and developing countries.

SAT’s innovative technology includes heart valves for the different pathology of Rheumatic Heart Disease and sophisticated, non-occlusive, helical balloon catheters that allow for their delivery directly to the heart, without the need for open-heart surgery or the expensive clinical infrastructure that is necessary in developed countries.

Specifically, SAT’s second-generation balloon expandable TAVR valve for rheumatic and degenerative aortic valve disease is designed to treat the entire aortic valve disease spectrum from calcific aortic stenosis to pure aortic regurgitation in patients with non-calcified, compliant annuli.

Clinical Trials

The Strait Access Technologies team have worked on the design, patent filings, prototype manufacturing and pre-clinical testing to reach the point when SAHPRA, the healthcare regulator in South Africa and the Human Ethics Committee (HEC) at Groote Schuur Hospital – the site of the world’s first successful human-to-human heart transplant in 1967 – have given approval for the first clinical implants in humans to commence.